Zobrazeno 1 - 10
of 296
pro vyhledávání: '"Elena Guerini"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 396-409 (2024)
Abstract Glofitamab is a novel T cell bispecific antibody developed for treatment of relapsed‐refractory diffuse large B cell lymphoma and other non‐Hodgkin's lymphoma indications. By simultaneously binding human CD20‐expressing tumor cells and
Externí odkaz:
https://doaj.org/article/7f592a5758c04aa3a48cc531488fe90e
Autor:
Francesco Pepe, Gianluca Russo, Alessandro Venuta, Claudia Scimone, Mariantonia Nacchio, Pasquale Pisapia, Gaia Goteri, Francesca Barbisan, Caterina Chiappetta, Angelina Pernazza, Domenico Campagna, Marco Giordano, Giuseppe Perrone, Giovanna Sabarese, Annalisa Altimari, Dario de Biase, Giovanni Tallini, Daniele Calistri, Elisa Chiadini, Laura Capelli, Alfredo Santinelli, Anna Elisa Gulini, Elisa Pierpaoli, Manuela Badiali, Stefania Murru, Riccardo Murgia, Elena Guerini Rocco, Konstantinos Venetis, Nicola Fusco, Denise Morotti, Andrea Gianatti, Daniela Furlan, Giulio Rossi, Laura Melocchi, Maria Russo, Caterina De Luca, Lucia Palumbo, Saverio Simonelli, Antonella Maffè, Paola Francia di Celle, Tiziana Venesio, Maria Scatolini, Enrico Grosso, Sara Orecchia, Matteo Fassan, Mariangela Balistreri, Elisabetta Zulato, Daniela Reghellin, Elena Lazzari, Maria Santacatterina, Maria Liliana Piredda, Manuela Riccardi, Licia Laurino, Elena Roz, Domenico Longo, Daniela Petronilla Romeo, Carmine Fazzari, Andrea Moreno-Manuel, Giuseppe Diego Puglia, Andrey D. Prjibelski, Daria Shafranskaya, Luisella Righi, Angela Listì, Domenico Vitale, Antonino Iaccarino, Umberto Malapelle, Giancarlo Troncone
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 73-95 (2024)
Abstract Introduction Biomarker testing is mandatory for the clinical management of patients with advanced non-small cell lung cancer (NSCLC). Myriads of technical platforms are now available for biomarker analysis with differences in terms of multip
Externí odkaz:
https://doaj.org/article/a35808bcabd148c5a14f08b4834ff7fc
Autor:
Konstantinos Venetis, Elham Sajjadi, Mariia Ivanova, Silvia Andaloro, Simona Pessina, Chiara Zanetti, Alberto Ranghiero, Gabriele Citelli, Chiara Rossi, Marco Lucioni, Umberto Malapelle, Fabio Pagni, Massimo Barberis, Elena Guerini‐Rocco, Giuseppe Viale, Nicola Fusco
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10725-10737 (2023)
Abstract Mucoepidermoid carcinoma (MEC) of the breast is an extremely rare salivary gland‐type tumor characterized by epidermoid, basaloid, intermediate, and/or mucinous cells arranged in solid and cystic patterns. Despite their triple‐negative p
Externí odkaz:
https://doaj.org/article/6d9a91c4d8154198a8750324f48d632e
Autor:
Konstantinos Venetis, Giulia Cursano, Carlo Pescia, Marianna D'Ercole, Francesca Maria Porta, Marta Cruz Blanco, Chiara Frascarelli, Mariia Ivanova, Elena Guerini Rocco, Nicola Fusco
Publikováno v:
The Journal of Liquid Biopsy, Vol 1, Iss , Pp 100002- (2023)
Breast cancer management has witnessed significant advancements, especially in the diagnosis and treatment response monitoring through the implementation of imaging techniques and tissue biopsy procedures. Nevertheless, there is potential for further
Externí odkaz:
https://doaj.org/article/14d5d38670da4708a8682a3ab562e3a0
Autor:
Elham Sajjadi, Konstantinos Venetis, Mariia Ivanova, Marianna Noale, Concetta Blundo, Eugenia Di Loreto, Giovanna Scarfone, Stefano Ferrero, Stefania Maggi, Paolo Veronesi, Viviana E. Galimberti, Giuseppe Viale, Fedro A. Peccatori, Nicola Fusco, Elena Guerini-Rocco
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundBreast cancer during pregnancy (PrBC) is a rare condition known for its aggressive clinical behavior. The presence of tumor-infiltrating lymphocytes (TILs) has been shown to have a significant impact on the prognosis of these patients. Desp
Externí odkaz:
https://doaj.org/article/5f479192c9ee4cc7b05e700cf3fcb210
Autor:
Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohis
Externí odkaz:
https://doaj.org/article/74a5081e0670443d91e62b68696a9dd0
Autor:
Joy C. Hsu, Felix Jaminion, Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N. Morcos, Nicolas Frey
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1357-1370 (2021)
Abstract Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK‐positive non‐small cell lung cancer. Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite M4 using ph
Externí odkaz:
https://doaj.org/article/3042761aeaaf42898d02ef39ffc33fc7
Autor:
Fabio Conforti, Laura Pala, Eleonora Pagan, Elena Guerini Rocco, Vincenzo Bagnardi, Emilia Montagna, Giulia Peruzzotti, Tommaso De Pas, Caterina Fumagalli, Silvana Pileggi, Chiara Pesenti, Sergio Marchini, Giovanni Corso, Caterina Marchio’, Anna Sapino, Rossella Graffeo, Laetitia Collet, Philippe Aftimos, Christos Sotiriou, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Marco Colleoni, Aron Goldhirsch
Publikováno v:
Breast, Vol 59, Iss , Pp 94-101 (2021)
Background: We report here for the first time, a comprehensive characterization of biological and clinical features of early-stage triple negative Invasive Lobular Carcinomas(TN-ILCs) Methods: We analyzed all consecutive patients with early-stage TN-
Externí odkaz:
https://doaj.org/article/0e41cdfb84f743128a8f6f2c40685bb2
Autor:
Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Donatella Gambini, Concetta Blundo, Letterio Runza, Stefano Ferrero, Elena Guerini-Rocco, Nicola Fusco
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Phosphatase and tensin homolog (PTEN) loss is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer. However, the clinical value of PTEN as a biomarker in these patients is controversial. We sou
Externí odkaz:
https://doaj.org/article/fe7008ea3e234d128db2c42c31ca8e8c
Autor:
Carmine Valenza, Francesca Maria Porta, Alessandra Rappa, Elena Guerini-Rocco, Giuseppe Viale, Massimo Barberis, Filippo de Marinis, Giuseppe Curigliano, Chiara Catania
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3384-3392 (2021)
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Externí odkaz:
https://doaj.org/article/114bffc9f29743a2ab9cfc96b4d8a82b